Company news

Dimerix Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete

December 29, 2024

Dimerix Receives $7.9M R&D Tax Incentive Rebate

November 14, 2024

NEPTUNE Study Network to Enhance Phase 3 Recruitment in US

October 31, 2024

Project PARASOL Update & Medical Advisory Board Appointment

October 27, 2024

ACTION3 Trial Recruitment and Multiregion Trial Site Update

September 15, 2024

First Paediatric Site Activated and Trial Update

September 11, 2024

First patient enters into Open Label Extension study

September 10, 2024

Preliminary Final Report

August 28, 2024

Adolescent Recruitment into ACTION3 Clinical Trial

July 3, 2024

Dimerix and Taiba enter into License Agreement for DMX-200

May 26, 2024

Dimerix Receives PIP Approval from the UK MHRA

April 30, 2024

Dimerix Completes $20M Placement

March 11, 2024

Dimerix Successfully Passes Efficacy Interim Analysis

March 10, 2024

PH3 Data Collection Complete for First Interim Analysis

February 26, 2024

Half-Year Financial Report & Appendix 4D - 31 December 2023

February 25, 2024

ACTION3 IND Approved in China

November 27, 2023

Dimerix Receives Initial Upfront Payment from Advanz Pharma

November 5, 2023

Dimerix Announces License Agreement for EU, Canada, ANZ

October 4, 2023

FDA Approves Qytovra Brand Name

September 24, 2023

Regulatory Approval received in Malaysia for ACTION3 Study

September 21, 2023

Dimerix Receives $8.9M R&D Tax Incentive Rebate

September 12, 2023

Successful Completion of 2nd DSMB Review of FSGS Trial

August 7, 2023

DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24

July 23, 2023

Approval received for Paediatric Investigation Plan from EMA

July 4, 2023

Dimerix confirms Phase 3 study design appropriate for China

July 2, 2023

Prospectus

June 26, 2023

Dimerix Announces Update on Successful Capital Raise

June 5, 2023

Rights Issue Prospectus

May 4, 2023

Reinstatement to Official Quotation

May 3, 2023

Entitlement offer and Convertible Note to raise $12 million

May 3, 2023

Voluntary Suspension

May 2, 2023

Half-Year Financial Report & Appendix 4D - 31 December 2022

February 26, 2023

DXB to Receive $2.8m in Prepayment of R&D Tax Incentive

February 16, 2023

Successful Completion of DSMB Review of Phase 3 FSGS Trial

February 8, 2023

FDA Confirms Inclusion of Paediatrics in ACTION3 Study

January 11, 2023

DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved

December 14, 2022

CLARITY 2.0 COVID-19 Study Outcome

December 12, 2022

Chair address and CEO presentation to AGM

November 28, 2022

Dimerix Receives A$6.0M R&D Tax Incentive Rebate

October 24, 2022

Appendix 4E and 2022 Annual Report

August 28, 2022

CLARITY 2.0 COVID-19 Study Concludes Recruitment

August 17, 2022

New Patent Family Application for DMX-700

August 8, 2022

DMX-700 Study Shows Significant 80% Reduction in Lung Injury

July 3, 2022

REMAP-CAP COVID-19 Study Analysis Update

June 26, 2022

New Clinical Trial for DMX-200 in Diabetic Kidney Disease

June 6, 2022

Phase 3 FSGS Kidney Trial First Patient Recruited

May 30, 2022

Dimerix presentation at Bioshares Biotech Summit

May 11, 2022

FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

May 8, 2022

Dimerix Receives A$3.7M R&D Tax Incentive Rebate

March 28, 2022

DSMB Change to REMAP-CAP COVID-19 Study

February 27, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 83 decks. Every deck is listed under its year.